与药物相关的高血压危机:FAERS数据库的不成比例性分析
Chunyong Xia1, Jie Liu2, Ya Gan3
1Department of Pharmacy, Chongqing University Jiangjin Hospital, No. 728, Dingshan Street, Jiangjin,Chongqing, 402260, China. 739488865@qq.com.
Naunyn-Schmiedeberg's archives of pharmacology
|November 13, 2025
概括
这项研究确定了许多具有高血压危机风险的药物,其中阿姆洛迪平,拉米普利尔和瓦尔萨坦显示早期不良事件发作. 需要进一步的研究来确认因果关系并指导临床实践.
科学领域:
- 药监和药物安全 药监和药物安全
- 临床药理学 临床药理学
- 公共卫生 公共卫生
背景情况:
- 药物不良事件 (ADEs) 可以导致严重的健康问题,包括高血压危机.
- 识别与高血压危机相关的药物对于患者安全和合理使用药物至关重要.
研究的目的:
- 使用FAERS数据库识别和评估可能导致高血压危机的药物不良事件 (ADEs) 的风险信号.
- 通过突出潜在的药物诱导高血压危机,为临床药物管理提供信息并促进合理的药物使用.
- 分析与特定药物相关的高血压危机的发病时间 (TTO).
主要方法:
- 利用FAERS数据库提取2004年第一季度至2025年第二季度与药物相关的高血压危机报告的统计数据.
- 采用了四种不成比例方法:报告赔率比率 (ROR),比例报告比率 (PRR),贝叶斯信心传播神经网络 (BCPNN) 和经验贝叶斯几何平均值 (EBGM).
- 通过使用韦布尔形状参数测试对已识别的不良事件进行了开始时间 (TTO) 分析.
主要成果:
- 总共有10,281份与药物相关的高血压危机报告被确定,涉及916种具有潜在风险信号的药物.
- 阿姆洛迪平,拉米普利和瓦尔萨坦是药物相关高血压危机报告数量最高的药物之一.
- 与高血压危机相关的ADE发生率最高的年龄组是18-65岁 (37.9%),30.69%的事件发生在药物开始后3天内.
结论:
- 许多药物与药物诱导高血压危机的潜在风险有关.
- 阿姆洛迪平,拉米普利和瓦尔萨坦显示出高血压危机发作的早期失败类型.
- 需要进一步调查以确定因果关系,并为更安全的药物管理提供临床决策信息.
更多相关视频
相关概念视频
01:11Renal Failure: Dose Adjustments
396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
01:21Drug Dosing: Obese Patients
189
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
189
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
181
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
181
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
288
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
288